X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with Biocon Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs BIOCON LTD - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA BIOCON LTD CIPLA/
BIOCON LTD
 
P/E (TTM) x 44.5 82.9 53.6% View Chart
P/BV x 3.8 7.8 48.9% View Chart
Dividend Yield % 0.3 0.2 211.9%  

Financials

 CIPLA   BIOCON LTD
EQUITY SHARE DATA
    CIPLA
Mar-17
BIOCON LTD
Mar-17
CIPLA/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs6221,162 53.5%   
Low Rs458483 95.0%   
Sales per share (Unadj.) Rs181.9194.6 93.5%  
Earnings per share (Unadj.) Rs12.934.4 37.4%  
Cash flow per share (Unadj.) Rs29.348.3 60.7%  
Dividends per share (Unadj.) Rs2.001.00 200.0%  
Dividend yield (eoy) %0.40.1 304.5%  
Book value per share (Unadj.) Rs155.7241.9 64.4%  
Shares outstanding (eoy) m804.51200.00 402.3%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.04.2 70.3%   
Avg P/E ratio x42.023.9 175.6%  
P/CF ratio (eoy) x18.417.0 108.2%  
Price / Book Value ratio x3.53.4 102.1%  
Dividend payout %15.52.9 534.6%   
Avg Mkt Cap Rs m434,516164,440 264.2%   
No. of employees `00023.09.2 249.5%   
Total wages/salary Rs m26,3387,470 352.6%   
Avg. sales/employee Rs Th6,349.14,213.9 150.7%   
Avg. wages/employee Rs Th1,143.0809.0 141.3%   
Avg. net profit/employee Rs Th449.3745.2 60.3%   
INCOME DATA
Net Sales Rs m146,30238,911 376.0%  
Other income Rs m2,2871,571 145.6%   
Total revenues Rs m148,58940,482 367.1%   
Gross profit Rs m24,7589,795 252.8%  
Depreciation Rs m13,2292,772 477.2%   
Interest Rs m1,594260 613.0%   
Profit before tax Rs m12,2228,334 146.6%   
Minority Interest Rs m0163 0.0%   
Prior Period Items Rs m-700-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,7981,616 111.2%   
Profit after tax Rs m10,3546,881 150.5%  
Gross profit margin %16.925.2 67.2%  
Effective tax rate %14.719.4 75.9%   
Net profit margin %7.117.7 40.0%  
BALANCE SHEET DATA
Current assets Rs m87,37040,477 215.9%   
Current liabilities Rs m33,08116,783 197.1%   
Net working cap to sales %37.160.9 60.9%  
Current ratio x2.62.4 109.5%  
Inventory Days Days8760 145.9%  
Debtors Days Days6283 75.2%  
Net fixed assets Rs m111,56745,073 247.5%   
Share capital Rs m1,6091,000 160.9%   
"Free" reserves Rs m123,64547,377 261.0%   
Net worth Rs m125,25448,377 258.9%   
Long term debt Rs m36,45421,082 172.9%   
Total assets Rs m209,53293,942 223.0%  
Interest coverage x8.733.1 26.2%   
Debt to equity ratio x0.30.4 66.8%  
Sales to assets ratio x0.70.4 168.6%   
Return on assets %5.77.6 75.0%  
Return on equity %8.314.2 58.1%  
Return on capital %8.512.6 67.4%  
Exports to sales %34.20-   
Imports to sales %8.30-   
Exports (fob) Rs m50,050NA-   
Imports (cif) Rs m12,203NA-   
Fx inflow Rs m51,06612,988 393.2%   
Fx outflow Rs m17,6787,899 223.8%   
Net fx Rs m33,3885,089 656.1%   
CASH FLOW
From Operations Rs m23,8246,400 372.2%  
From Investments Rs m-13,127-4,985 263.3%  
From Financial Activity Rs m-13,239-1,775 745.8%  
Net Cashflow Rs m-2,478-473 523.9%  

Share Holding

Indian Promoters % 16.0 40.4 39.6%  
Foreign collaborators % 20.8 20.6 101.0%  
Indian inst/Mut Fund % 12.2 8.4 145.2%  
FIIs % 23.7 10.7 221.5%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 19.9 131.7%  
Shareholders   161,166 109,995 146.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   CADILA HEALTHCARE  TTK HEALTHCARE  SHASUN PHARMA  STRIDES SHASUN LTD  J.B.CHEMICALS  

Compare CIPLA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Strong Finish to the Week; Metal & Pharma Stocks Gain(Closing)

Indian share markets finished the trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Feb 23, 2018 03:35 PM

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS